Our study suggests that regulation of HRAS in non-small-cell lung carcinoma vary from that of KRAS. RAS isoform differences have been identified at the level of protein translation and provide a potential explanation for the highest frequency of KRAS mutation in cancers. The gene discussed is HRAS; the disease is cancer.